Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 13
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Alligator Bioscience has renegotiated the outstanding loan from Fenja Capital and received subscription intentions from members of the Board of Directors and management
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Alligator Bioscience announces that 85% of the warrant programme TO 12 has been secured and that the outstanding loan has been renegotiated
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation
Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly wit ...
Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Transaction valued at €3.5 million The partners have enjoyed a successful discovery collaboration since 2021 Lund, Sweden – Allig ...
Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously repo ...
Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement
Orion selects lead antibodies from the second discovery program Collaboration aims to discover and develop new bispecific antibody cancer th ...